EC
GOSS icon

EntryPoint Capital’s Gossamer Bio GOSS Stock Holding History

EntryPoint Capital’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-105,085
Closed -$326K – 811
2025
Q4 		$326K Buy
105,085
+53,821
+105% +$154K 0.13% 324
2025
Q3 		$135K Buy
+51,264
New +$113K 0.05% 603

Other funds holding GOSS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

EntryPoint Capital's GOSS Position: Q1 2026 in Review

EntryPoint Capital sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 105,085 shares — an estimated $326K sold.

EntryPoint Capital first reported a position in GOSS in Q3 2025 and held it in 2 quarters. The position peaked at $326K in Q4 2025. 184 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • EntryPoint Capital reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
  • EntryPoint Capital sold 105,085 Gossamer Bio shares in Q1 2026, an estimated $326K.
  • EntryPoint Capital first reported a position in Gossamer Bio in Q3 2025 and held it in 2 quarters.
  • EntryPoint Capital's Gossamer Bio position peaked at $326K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.